Jan 7 (Reuters) - Immutep Ltd IMM.AX :
* ENTERS CLINICAL TRIAL COLLABORATION WITH CYTLIMIC TO TEST EFTILAGIMOD ALPHA
* IMMUTEP IS ELIGIBLE TO RECEIVE UP TO US$4.5 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF MILESTONES BY CYTLIMIC
* ENTERED INTO A SUPPLY AGREEMENT TO PROVIDE EFTI TO CYTLIMIC FOR MANUFACTURE OF CYT001
* ENTERED SERVICE AGREEMENT WHERE IMMUTEP WILL PROVIDE TECHNICAL SUPPORT SERVICES TO CYTLIMIC DURING DEVELOPMENT & COMMERCIALISATION OF CYT00